Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma

A compound of Formula I:

• Wherein R1 and R2 are independently chosen from hydrogen, C1-4alkyl;
• R3 is selected from hydrogen, C1-4alkyl, or R2 and R3 can complete a pyrrolidine or piperidine ring, which can be substituted with C1-4alkyl;
• R4 is hydrogen, C1-4alkyl, or when Y is carbon R4 can also be halogen;
• R5 and R6 are independently chosen from hydrogen, halogen, C1-6-alkyl, C1-6-alkylthio, C1-6-alkylsulfonyl, C1-6-alkylsulfoxide, nitrile, C1-6-alkyl substituted with halogen;
• R7 is chosen from C═OR9, S(O)mR10, NR1—(C═O)—R11,
• C1-6-alkyl substituted with:
• hydroxyl, C1-6alkoxy, NR12R13, CO2H, CO2C1-6alkyl, C(═O)NR12R13 or S(O)mNR12R13, or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C1-4alkyl;
• or R7 can be chosen from a heterocyclic ring selected from oxazol-2-yl, 4,5-dihydro-oxazol-2-yl, 5,6-dihydro-[1,3]oxazin-2-yl, thiazol-2-yl, 4,5-dihydro-thiazol-2-yl, benzoxazol-2-yl, benzothiazol-2-yl, imidazol-2-yl, imidazolidin-2-yl, [1,2,4]oxadiazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]thiadiazol-5-yl, or [1,2,4]thiadiazol-3-yl which can be unsubstituted or substituted with C1-4alkyl;
• but R7 cannot be hydrogen, lower alkyl, hydroxyl, lower alkoxy, amino, mono- or di-loweralkyl amino, lower alkanoylamino, or halogen;
• R9 is chosen from hydroxyl, C1-6alkoxy, NR14R15, C1-6alkyl, or C2-6alkyl substituted with hydroxyl, C1-6alkoxy, NR12R13, CO2H, CO2C1-6alkyl, S(O)mNR12R13, halogen, or a heterocyclic ring selected from pyrrolidin-2-yl, imidazo-2-yl, imidazo4-yl, morpholin-3-yl, oxazolyl, isoxazolyl, thiazolyl, or tetrazolyl, which can be unsubstituted or substituted with C1-4alkyl;
• R10 is chosen from NR12R13, C1-6alkyl, or C2-6alkyl substituted with hydroxyl, C1-6alkoxy, NR11R12, CO2H, CO2C1-6alkyl;
• R11 is C1-6alkyl substituted with hydroxyl, C1-6alkoxy, or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C1-4alkyl;
• R12 and R3 are independently selected from hydrogen, C1-6alkyl, C2-6alkyl substituted with hydroxyl, C1-6alkoxy, or halogen, or R12, R13, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C1-4alkyl or C1-4alkyl substituted with hydroxy or C1-4alkoxy;
• R14 and R15 are independently selected from hydrogen, C1-6alkyl, hydroxyl, C1-6alkoxy, C2-6alkyl substituted with hydroxyl, C1-6alkoxy, halogen or a heterocyclic ring selected from pyrrolidin-2-yl, imidazo-2-yl, imidazo-4-yl, morpholin-3-yl, oxazolyl, isoxazolyl, thiazolyl, tetrazolyl, which can be unsubstituted or substituted with C1-4alkyl, or R14, R15, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C1-4alkyl or C1-4alkyl substituted with hydroxy or C1-4alkoxy;
• R16 is chosen from no atom, hydrogen, C1-6alkyl, or C1-6alkyl substituted with halogen, HO, or C1-6alkoxy;
• ---═double or single bond in the oxazole ring;
• when R16 is no atom, --- is a double bond, and when --- is a single bond, R7is Q, where Q is oxygen, sulfur, or NR1 attached to the oxazole ring by a double bond;
• m is 0-2;
• A is N or CH;
• X and Y are either N or C, wherein X and Y cannot be the same;
• and the dashed bonds in this ring denote a suitably appointed single and double bond;
• and
• pharmaceutically acceptable salts, solvates, or prodrugs thereof.

A compound selected from the group consisting of:

• (S)-2-[7-(Methoxymethyl)-1H-pyrazolo[3,4-e]benzoxazol-1-yl]-1-methylethylamine;
• 1-[(S)-2-Aminopropyl]-1H-pyrazolo[3,4-e]benzoxazole -7-carboxylic acid amide;
• 1-[(S)-2-Aminopropyl]-1H-pyrazolo[3,4-e]benzoxazole -7-carboxylic acid methylamide;
• and
• pharmaceutically acceptable salts, solvates and prodrugs thereof.

A topical ophthalmic composition comprising a pharmaceutically effective amount of a compound in an ophthalmically acceptable vehicle, wherein the compound is of Formula I:

• Wherein R1 and R2 are independently chosen from hydrogen, C1-4alkyl;
• R3 is selected from hydrogen, C1-4alkyl, or R2 and R3 can complete a pyrrolidine or piperidine ring, which can be substituted with C1-4alkyl;
• R4 is hydrogen, C1-4alkyl, or when Y is carbon R4 can also be halogen;
• R5 and R6 are independently chosen from hydrogen, halogen, C1-6alkyl, C1-6alkylthio, C1-6alkylsulfonyl, C1-6alkylsulfoxide, nitrile, C1-6alkyl substituted with halogen;
• R7 is chosen from C═OR9, S(O)mR10, NR1—(C═O)—R11,
• C1-6alkyl substituted with:
• hydroxyl, C1-6alkoxy, NR12R13, CO2H, CO2C1-6alkyl, C(═O)NR12R13 or S(O)mNR12R13, or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C1-4alkyl;
• or R7 can be chosen from a heterocyclic ring selected from oxazol-2-yl, 4,5-dihydro-oxazol-2-yl, 5,6-dihydro-[1,3]oxazin-2-yl, thiazol-2-yl, 4,5-dihydro-thiazol-2-yl, benzoxazol-2-yl, benzothiazol-2-yl, imidazol-2-yl, imidazolidin-2-yl, [1,2,4]oxadiazol-5-yl, [1,2,4]oxadiazol-3-yl, [1,2,4]thiadiazol-5-yl, or [1,2,4]thiadiazol-3-yl which can be unsubstituted or substituted with C1-4alkyl;
• but R7 cannot be hydrogen, lower alkyl, hydroxyl, lower alkoxy, amino, mono- or di-loweralkyl amino, lower alkanoylamino, or halogen;
• R9 is chosen from hydroxyl, C1-6alkoxy, NR14R15, C1-6alkyl, or C2-6alkyl substituted with hydroxyl, C1-6alkoxy, NR12R13, CO2H, CO2C1-6alkyl, S(O)mNR12R13, halogen, or a heterocyclic ring selected from pyrrolidin-2-yl, imidazo-2-yl, imidazo-4-yl, morpholin-3-yl, oxazolyl, isoxazolyl, thiazolyl, or tetrazolyl, which can be unsubstituted or substituted with C1-4alkyl;
• R10 is chosen from NR12R13, C1-6alkyl, or C2-6alkyl substituted with hydroxyl, C1-6alkoxy, NR11R12, CO2H, CO2C1-6alkyl;
• R11 is C1-6alkyl substituted with hydroxyl, C1-6alkoxy, or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C1-4alkyl;
• R12 and R13 are independently selected from hydrogen, C1-6alkyl, C2-6alkyl substituted with hydroxyl, C1-6alkoxy, or halogen, or R12, R13, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C1-4alkyl or C1-4alkyl substituted with hydroxy or C1-4alkoxy;
• R14 and R15 are independently selected from hydrogen, C1-6alkyl, hydroxyl, C1-6alkoxy, C2-6alkyl substituted with hydroxyl, C1-6alkoxy, halogen or a heterocyclic ring selected from pyrrolidin-2-yl, imidazo-2-yl, imidazo4-yl, morpholin-3-yl, oxazolyl, isoxazolyl, thiazolyl, tetrazolyl, which can be unsubstituted or substituted with C1-4alkyl, or R14, R15, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C1-4alkyl or C1-4alkyl substituted with hydroxy or C1-4alkoxy;
• R16 is chosen from no atom, hydrogen, C1-6alkyl, or C1-6alkyl substituted with halogen, HO, or C1-6alkoxy;
• ---═double or single bond in the oxazole ring;
• when R16 is no atom, --- is a double bond, and when --- is a single bond, R7 is Q, where Q is oxygen, sulfur, or NR1 attached to the oxazole ring by a double bond;
• m is 0-2;
• A is N or CH;
• X and Y are either N or C, wherein X and Y cannot be the same;
• and the dashed bonds in this ring denote a suitably appointed single and double bond;
• and
• pharmaceutically acceptable salts, solvates, or prodrugs thereof.